| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5825002 | Clinical Therapeutics | 2015 | 11 Pages |
Abstract
The GLP-1 receptor agonists have proven efficacy in the treatment of type 2 diabetes and may provide patients with additional nonglycemic benefits, including significant weight loss and decreased systolic blood pressure. The newer once-weekly formulations are more convenient than the BID and once-daily medications, which could improve adherence and may be more attractive to providers and patients.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Christopher A. Lindamood, James R. PharmD, CDE,